摘要
探讨比索洛尔联合单硝酸异山梨酯片治疗慢性心力衰竭的疗效及对炎症微循环、心功能的影响。选择医院于2021年2月—2023年2月期间收治的254例慢性心力衰竭患者随机分成对照组(127例)和研究组(127例)。对照组给予单硝酸异山梨酯片,研究组给予比索洛尔联合单硝酸异山梨酯片,两组均治疗6个月。对比两组的临床疗效、炎症指标[C反应蛋白(CRP)、炎性因子可溶性CD40配体(sCD40L)、白介素18(IL-18)]、血管内皮功能[降钙素基因相关肽(CGRP)、内皮素(ET)、一氧化氮(NO)]、心肌纤维化指标[结缔组织生长因子(CTGF)、转化生长因子-β1(TGF-β1)、N端脑钠肽前体(NT-proBNP)]、心功能[左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、左室射血分数(LVEF)]及不良反应。研究组的总有效率为96.06%,高于对照组的85.83%(P<0.05)。研究组在CRP降低、sCD40L降低、IL-18降低、CGRP增加、NO增加、ET降低、CTGF降低、TGF-β1降低、NT-proBNP降低、LVEDD降低、LVESD降低和LVEF增加方面均优于对照组(P<0.05)。两组晕眩、头痛、恶心及皮疹等不良反应的发生率差异无统计学意义(P>0.05)。比索洛尔联合单硝酸异山梨酯片治疗慢性心力衰竭的疗效确切,能够抑制炎症反应,改善血管内皮功能、延缓心肌纤维化和改善心功能,安全性较高,值得在临床应用和推广。
To investigate the efficacy of bisoprolol combined with isosorbide mononitrate tablets in the treatment of chronic heart failure and the effects on inflammatory microcirculation and cardiac function,a total of 254 patients with chronic heart failure admitted to a selected hospital between February 2021 and February 2023 were randomly divided into a control group(127 cases)and a study group(127 cases).The control group was given isosorbide mononitrate tablets,and the study group was given bisoprolol combined with isosorbide mononitrate tablets.Both groups were treated for 6 months.The clinical efficacy,inflammatory indexes[C-reactive protein(CRP),inflammatory factor soluble CD40 ligand(sCD40L),interleukin18(IL-18)],vascular endothelial function[calcitonin gene-related peptide(CGRP),endothelin(ET),nitric oxide(NO)],myocardial fibrosis indexes connective tissue growth factor(TGF),transforming growth faction-β1(TGF-β1),NT-proBNP,cardiac function[left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD),left ventricular ejection fraction(LVEF)]and adverse reactions were compared between the two groups.The total effective rate of the study group was 96.06%,which was higher than the 85.83%of the control group(P<0.05).The study group showed superior results compared to the control group in terms of reducing CRP,sCD40L,and IL-18 levels,as well as increasing CGRP and NO levels,reducing ET levels,and decreasing CTGF,TGF-β1,NT-proBNP,LVEDD,and LVESD levels,while increasing LVEF(P<0.05).There was no statistically significant difference in the incidence of adverse reactions such as dizziness,headache,nausea,and rash between the two groups(P>0.05).Bisoprolol combined with isosorbide mononitrate tablets has a definite effect in the treatment of chronic heart failure,which can inhibit inflammation,improve vascular endothelial function,delay myocardial fibrosis and improve cardiac function.It is safe and worthy of clinical application and promotion.
作者
尹航
刘佳
刘培培
崔文文
高洁
孙玉翠
YIN Hang;LIU Jia;LIU Peipei;CUI Wenwen;GAO Jie;SUN Yucui(Department of Cardiology,Cangzhou People's Hospital,Cangzhou 061000,China)
出处
《药物生物技术》
2025年第3期349-353,共5页
Pharmaceutical Biotechnology
基金
沧州市重点研发计划指导项目(No.222106146)。
关键词
比索洛尔
单硝酸异山梨酯片
慢性心力衰竭
血管内皮功能
炎症反应
心功能
心肌纤维化
Bisoprolol
Isosorbide mononitrate tablets
Chronic heart failure
Vascular endothelial function
Inflammatory response
Heart function
Myocardial fibrosis
